202 related articles for article (PubMed ID: 25963988)
1. Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.
Lempers VJ; Schouten JA; Hunfeld NG; Colbers A; van Leeuwen HJ; Burger DM; Verweij PE; Pickkers P; Brüggemann RJ
Antimicrob Agents Chemother; 2015 Aug; 59(8):4403-9. PubMed ID: 25963988
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Anidulafungin in Critically Ill Intensive Care Unit Patients with Suspected or Proven Invasive Fungal Infections.
Brüggemann RJ; Middel-Baars V; de Lange DW; Colbers A; Girbes AR; Pickkers P; Swart EL
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872072
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
Martial LC; Ter Heine R; Schouten JA; Hunfeld NG; van Leeuwen HJ; Verweij PE; de Lange DW; Pickkers P; Brüggemann RJ
Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
[TBL] [Abstract][Full Text] [Related]
5. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Mehta PA; Vinks AA; Filipovich A; Bleesing J; Jodele S; Jordan MB; Marsh R; Tarin R; Edwards S; Fearing D; Lawrence J; Davies SM
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1458-62. PubMed ID: 20546908
[TBL] [Abstract][Full Text] [Related]
6. Low Caspofungin Exposure in Patients in Intensive Care Units.
van der Elst KC; Veringa A; Zijlstra JG; Beishuizen A; Klont R; Brummelhuis-Visser P; Uges DR; Touw DJ; Kosterink JG; van der Werf TS; Alffenaar JC
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855112
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of caspofungin in ICU patients.
Muilwijk EW; Schouten JA; van Leeuwen HJ; van Zanten AR; de Lange DW; Colbers A; Verweij PE; Burger DM; Pickkers P; Brüggemann RJ
J Antimicrob Chemother; 2014 Dec; 69(12):3294-9. PubMed ID: 25139840
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects.
Undre NA; Stevenson P; Wilbraham D
Int J Clin Pharmacol Ther; 2014 Mar; 52(3):237-44. PubMed ID: 24472403
[TBL] [Abstract][Full Text] [Related]
9. Micafungin concentrations in the plasma and burn eschar of severely burned patients.
Sasaki J; Yamanouchi S; Kudo D; Endo T; Nomura R; Takuma K; Kushimoto S; Shinozawa Y; Kishino S; Hori S; Aikawa N
Antimicrob Agents Chemother; 2012 Feb; 56(2):1113-5. PubMed ID: 22083486
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
[TBL] [Abstract][Full Text] [Related]
11. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
[TBL] [Abstract][Full Text] [Related]
12. Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.
Walsh TJ; Goutelle S; Jelliffe RW; Golden JA; Little EA; DeVoe C; Mickiene D; Hayes M; Conte JE
Antimicrob Agents Chemother; 2010 Aug; 54(8):3451-9. PubMed ID: 20439610
[TBL] [Abstract][Full Text] [Related]
13. Prediction of micafungin area under the curve data by using peak concentration: applicability and utility in antifungal therapy.
Srinivas NR
Future Microbiol; 2016; 11(4):485-90. PubMed ID: 27070500
[TBL] [Abstract][Full Text] [Related]
14. Micafungin Plasma Levels Are Not Affected by Continuous Renal Replacement Therapy: Experience in Critically Ill Patients.
Vossen MG; Knafl D; Haidinger M; Lemmerer R; Unger M; Pferschy S; Lamm W; Maier-Salamon A; Jäger W; Thalhammer F
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584142
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis.
Würthwein G; Cornely OA; Trame MN; Vehreschild JJ; Vehreschild MJ; Farowski F; Müller C; Boos J; Hempel G; Hallek M; Groll AH
Antimicrob Agents Chemother; 2013 Apr; 57(4):1664-71. PubMed ID: 23335740
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.
Jullien V; Azoulay E; Schwebel C; Le Saux T; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Cour M; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Wolff M; Timsit JF;
J Antimicrob Chemother; 2017 Jan; 72(1):181-189. PubMed ID: 27609051
[TBL] [Abstract][Full Text] [Related]
17. High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis.
Auriti C; Falcone M; Ronchetti MP; Goffredo BM; Cairoli S; Crisafulli R; Piersigilli F; Corsetti T; Dotta A; Pai MP
Antimicrob Agents Chemother; 2016 Dec; 60(12):7333-7339. PubMed ID: 27697761
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of micafungin in neonates and young infants.
Hope WW; Smith PB; Arrieta A; Buell DN; Roy M; Kaibara A; Walsh TJ; Cohen-Wolkowiez M; Benjamin DK
Antimicrob Agents Chemother; 2010 Jun; 54(6):2633-7. PubMed ID: 20308367
[TBL] [Abstract][Full Text] [Related]
19. Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.
García-de-Lorenzo A; Luque S; Grau S; Agrifoglio A; Cachafeiro L; Herrero E; Asensio MJ; Sánchez SM; Roberts JA
Antimicrob Agents Chemother; 2016 Oct; 60(10):5914-21. PubMed ID: 27458229
[TBL] [Abstract][Full Text] [Related]
20. [Differential pharmacokinetic characteristics of micafungin. Experience in special populations].
Grau Cerrato S; Luque Pardos S; Ferrández Quirante O
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():10-4. PubMed ID: 21420571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
